Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).

Cancer prevention research (Philadelphia, Pa.) - 1 Mar 2021

Ulusan Ahmet M, Rajendran Praveen, Dashwood Wan Mohaiza, Yavuz Omer F, Kapoor Sabeeta, Gustafson Trace A, Savage Michelle I, Brown Powel H, Sei Shizuko, Mohammed Altaf, Vilar Eduardo, Dashwood Roderick H

Abstract excerpt

A clinical trial in patients with familial adenomatous polyposis (FAP) demonstrated that sulindac plus erlotinib (SUL+ERL) had good efficacy in the duodenum and colon, but toxicity issues raised concerns for long-term prevention. We performed a biomarker study in the polyposis in rat colon (Pirc) model, observing phosphorylated Erk inhibition in colon polyps for up to 10 days after discontinuing ERL+SUL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenomatous Polyposis Coli
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colonic Neoplasms

Share to Colonic Polyps

Share to Dose-Response Relationship, Drug

Share to Erlotinib Hydrochloride

Share to Genes, APC

Share to Intestinal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33277315
DOI: 10.1158/1940-6207.CAPR-20-0262
PMCID: PMC8137519

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).PMID 33277315Read ↗

Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.Semantic proximity Read ↗

Evaluation of EGFR and COX pathway inhibition in human colon organoids of serrated polyposis and other hereditary cancer syndromes.Semantic proximity Read ↗

Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention?Semantic proximity Read ↗

Strategies for prevention of colorectal cancer: pharmaceutical and nutritional interventions.Semantic proximity Read ↗

Resveratrol prevents tumorigenesis in mouse model of Kras activated sporadic colorectal cancer by suppressing oncogenic Kras expression.Semantic proximity Read ↗

Leveraging WNT Hyperactivation to Kill Colorectal Cancer While Rejuvenating Healthy IntestineSemantic proximity Read ↗

Apc-driven colon carcinogenesis in Pirc rat is strongly reduced by polyethylene glycol.Semantic proximity Read ↗

Chemoprevention in familial adenomatous polyposis.Semantic proximity Read ↗

Combination of a pesco-vegetarian diet with non-steroidal anti-inflammatory drugs for colorectal cancer prevention: tumor suppression and gut microbiota modulation in Apc- mutated PIRC ratsSemantic proximity Read ↗

Antioxidants Promote Intestinal Tumor Progression in MiceSemantic proximity Read ↗

Wild-type K-ras has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation.Semantic proximity Read ↗

Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.